T-Cypher Bio extends footprint in purpose-built laboratory space at Abingdon Science Park, Oxford

The Medical News ·
Health & Medicine United Kingdom

T-Cypher Bio ("T-Cypher), a biotechnology company developing novel T cell receptor (TCR)-based T cell engagers that target high copy number antigens, today announced its relocation to Abingdon Science Park, Oxford, UK.

Read original article on The Medical News →

Related news